Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas

  • Leukemia. 2019 Aug;33(8):2105-2110. doi: 10.1038/s41375-019-0440-x.
Yonghui Sun  1 ,  Ning Ding  2 ,  Yuqin Song  2 ,  Zimo Yang  1 ,  Wanli Liu  3 ,  Jun Zhu  4 ,  Yu Rao  5
Affiliations
  • 1. MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, 100084, P.R. China.
  • 2. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China.
  • 3. MOE Key Laboratory of Protein Sciences, Center for Life Sciences, Institute for Immunology, School of Life Sciences, Beijing Key Lab for Immunological Research on Chronic Diseases, Tsinghua University, Beijing, 100084, China. [email protected].
  • 4. Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China. [email protected].
  • 5. MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, 100084, P.R. China. [email protected].
PMID: 30858551 DOI: 10.1038/s41375-019-0440-x
Products